DE602004023951D1 - Pna-monomer und vorstufe - Google Patents
Pna-monomer und vorstufeInfo
- Publication number
- DE602004023951D1 DE602004023951D1 DE602004023951T DE602004023951T DE602004023951D1 DE 602004023951 D1 DE602004023951 D1 DE 602004023951D1 DE 602004023951 T DE602004023951 T DE 602004023951T DE 602004023951 T DE602004023951 T DE 602004023951T DE 602004023951 D1 DE602004023951 D1 DE 602004023951D1
- Authority
- DE
- Germany
- Prior art keywords
- sub
- halogenated
- alkoxy
- alkyl
- oligomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000178 monomer Substances 0.000 title abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 108091093037 Peptide nucleic acid Proteins 0.000 abstract 4
- 229910052794 bromium Inorganic materials 0.000 abstract 4
- 229910052801 chlorine Inorganic materials 0.000 abstract 4
- 229910052731 fluorine Inorganic materials 0.000 abstract 4
- 229910052740 iodine Inorganic materials 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002825 nitriles Chemical class 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 abstract 1
- 235000008206 alpha-amino acids Nutrition 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Chemical group 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/46—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49079203P | 2003-07-28 | 2003-07-28 | |
| PCT/IB2004/050406 WO2005009998A1 (en) | 2003-07-28 | 2004-04-07 | Pna monomer and precursor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004023951D1 true DE602004023951D1 (de) | 2009-12-17 |
Family
ID=34102993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004023951T Expired - Lifetime DE602004023951D1 (de) | 2003-07-28 | 2004-04-07 | Pna-monomer und vorstufe |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7211668B2 (de) |
| EP (1) | EP1651642B1 (de) |
| JP (1) | JP4441535B2 (de) |
| KR (2) | KR100752552B1 (de) |
| CN (1) | CN1829714B (de) |
| AT (1) | ATE447569T1 (de) |
| DE (1) | DE602004023951D1 (de) |
| DK (1) | DK1651642T3 (de) |
| WO (1) | WO2005009998A1 (de) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030084444A (ko) * | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
| EP1855694B1 (de) | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense-zusammensetzung zur behandlung von muskelatrophie |
| US8198039B2 (en) * | 2007-09-04 | 2012-06-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biosensors and related methods |
| KR101072899B1 (ko) * | 2008-01-21 | 2011-10-17 | 주식회사 파나진 | 아미노산 스페이서가 결합된 펩티드 핵산의 합성 및 그의응용 |
| KR101360037B1 (ko) * | 2008-12-02 | 2014-02-07 | 현대자동차주식회사 | 차량용 ｌｎｇ 연료 탱크 |
| CN102575252B (zh) | 2009-06-01 | 2016-04-20 | 光环生物干扰疗法公司 | 用于多价rna干扰的多核苷酸、组合物及其使用方法 |
| JP5991922B2 (ja) | 2009-11-13 | 2016-09-14 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンス抗ウイルス性化合物およびインフルエンザウイルス感染を処置するための方法 |
| WO2011064552A1 (en) | 2009-11-30 | 2011-06-03 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
| WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
| EP2545173A2 (de) | 2010-03-12 | 2013-01-16 | Sarepta Therapeutics, Inc. | Antisense-modulation von nukleären hormonrezeptoren |
| CN103118692A (zh) | 2010-04-26 | 2013-05-22 | Atyr医药公司 | 与半胱氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CN103096911B (zh) | 2010-04-27 | 2018-05-29 | Atyr 医药公司 | 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| JP6008837B2 (ja) | 2010-04-28 | 2016-10-19 | エータイアー ファーマ， インコーポレイテッド | アラニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| CN103097523B (zh) | 2010-04-29 | 2016-09-28 | Atyr医药公司 | 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CN103118693B (zh) | 2010-04-29 | 2017-05-03 | Atyr 医药公司 | 与缬氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| EP2566495B1 (de) | 2010-05-03 | 2017-03-01 | aTyr Pharma, Inc. | Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-alpha-trna-synthetasen |
| US8961961B2 (en) | 2010-05-03 | 2015-02-24 | a Tyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases |
| CA2797978C (en) | 2010-05-03 | 2019-12-03 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases |
| JP6008844B2 (ja) | 2010-05-04 | 2016-10-19 | エータイアー ファーマ， インコーポレイテッド | ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| ES2816898T3 (es) | 2010-05-13 | 2021-04-06 | Sarepta Therapeutics Inc | Compuestos que modulan la actividad de señalización de las interleucinas 17 y 23 |
| JP6396656B2 (ja) | 2010-05-14 | 2018-09-26 | エータイアー ファーマ， インコーポレイテッド | フェニルアラニルβｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| WO2011146410A2 (en) | 2010-05-17 | 2011-11-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases |
| AU2011258106B2 (en) | 2010-05-27 | 2017-02-23 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
| CN103118695B (zh) | 2010-07-12 | 2016-08-03 | Atyr医药公司 | 与甘氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现 |
| AU2011293294B2 (en) | 2010-08-25 | 2016-03-24 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases |
| US10100305B2 (en) | 2011-07-15 | 2018-10-16 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| EP2788488B1 (de) | 2011-12-08 | 2018-03-21 | Sarepta Therapeutics, Inc. | Verfahren zur behandlung von progeroid-laminopathien mittels oligonukleotidanalog-anzielung von humanen lmna |
| KR101742954B1 (ko) * | 2012-05-31 | 2017-06-02 | 페넥스 파마슈티컬스 아게 | 고아 핵 수용체 ror[감마]의 조절제로서의 카복사미드 또는 설폰아미드가 치환된 티아졸 및 관련된 유도체 |
| US10006909B2 (en) | 2012-09-28 | 2018-06-26 | Vibrant Holdings, Llc | Methods, systems, and arrays for biomolecular analysis |
| CN103145714A (zh) * | 2013-03-13 | 2013-06-12 | 苏州维泰生物技术有限公司 | 公斤级合成pna的方法 |
| MX2016002934A (es) | 2013-09-05 | 2016-12-20 | Sarepta Therapeutics Inc | Inclusion del exon 2 inducida por antisentido en la alfa-glucosidasa ácida. |
| US10517898B2 (en) | 2014-11-20 | 2019-12-31 | The Regents Of The University Of California | Compositions and methods related to hematologic recovery |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| MA50829A (fr) | 2015-06-01 | 2018-04-11 | Sarepta Therapeutics Inc | Exclusion d'exon induite pat technologie antisens dans le collagène de type vii |
| CA2995995A1 (en) | 2015-08-24 | 2017-03-02 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
| US20190177723A1 (en) | 2015-10-09 | 2019-06-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| JP6944942B2 (ja) | 2016-02-02 | 2021-10-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 |
| EA201892366A1 (ru) | 2016-04-18 | 2019-03-29 | Сарепта Терапьютикс, Инк. | Антисмысловые олигомеры и способы их применения для лечения заболеваний, связанных с геном кислой альфа-глюкозидазы |
| CA3022303A1 (en) | 2016-04-29 | 2017-11-02 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues targeting human lmna |
| EP3478697A1 (de) | 2016-06-30 | 2019-05-08 | Sarepta Therapeutics, Inc. | Exon-skipping-oligomere für muskeldystrophie |
| WO2018017814A1 (en) | 2016-07-20 | 2018-01-25 | President And Fellows Of Harvard College | Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections |
| US11202818B2 (en) | 2016-09-14 | 2021-12-21 | President And Fellows Of Harvard College | Methods and compositions for modulating erythropoiesis |
| WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
| NZ755422A (en) | 2016-12-19 | 2023-06-30 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| MD3554552T2 (ro) | 2016-12-19 | 2022-12-31 | Sarepta Therapeutics Inc | Conjugați oligomeri de omitere a exonilor pentru distrofie musculară |
| MX2019006882A (es) | 2016-12-19 | 2019-08-16 | Sarepta Therapeutics Inc | Conjugados de oligomeros de omision de exon para distrofia muscular. |
| US11767520B2 (en) | 2017-04-20 | 2023-09-26 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| WO2018218250A2 (en) | 2017-05-26 | 2018-11-29 | Vibrant Holdings, Llc | Photoactive compounds and methods for biomolecule detection and sequencing |
| EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| WO2019067979A1 (en) | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY |
| EP3687577A1 (de) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Kombinationstherapien zur behandlung von muskeldystrophie |
| US20200248178A1 (en) | 2017-09-28 | 2020-08-06 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
| US10758629B2 (en) | 2018-05-29 | 2020-09-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| EP4219717A3 (de) | 2018-06-13 | 2023-12-20 | Sarepta Therapeutics, Inc. | Exon-skipping-oligomere für muskeldystrophie |
| TW202020153A (zh) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| US11273137B2 (en) | 2018-09-04 | 2022-03-15 | Board Of Trustees Of Michigan State University | Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene |
| CA3122281A1 (en) | 2018-12-13 | 2020-06-18 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| CA3132199A1 (en) | 2019-03-12 | 2020-09-17 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
| WO2020214763A1 (en) | 2019-04-18 | 2020-10-22 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| US20220226269A1 (en) | 2019-06-12 | 2022-07-21 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
| KR20210082091A (ko) | 2019-12-24 | 2021-07-02 | 주식회사 시선바이오머티리얼스 | 개질된 감마탄소 골격 화합물 및 이의 제조방법 |
| KR102403904B1 (ko) | 2019-12-24 | 2022-06-02 | 주식회사 시선바이오머티리얼스 | 용액공정상 pna 올리고머의 제조방법 |
| KR20230004456A (ko) | 2020-03-04 | 2023-01-06 | 리제너론 파아마슈티컬스, 인크. | 면역 요법에 대한 종양 세포의 감작화를 위한 방법 및 조성물 |
| US20230285357A1 (en) | 2020-05-27 | 2023-09-14 | The Regents Of The University Of California | Compositions and methods for transdifferentiating cells |
| WO2022056454A2 (en) | 2020-09-14 | 2022-03-17 | President And Fellows Of Harvard College | Methods and compositions for treating hpv-positive cancers |
| AU2021344422A1 (en) | 2020-09-16 | 2023-05-04 | Gordon J. Freeman | Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy |
| AU2022358322A1 (en) | 2021-09-30 | 2024-05-16 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
| WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
| WO2023091704A1 (en) | 2021-11-18 | 2023-05-25 | Circularis Biotechnologies, Inc. | Compositions and methods for production of circular nucleic acid molecules |
| WO2023150181A1 (en) | 2022-02-01 | 2023-08-10 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
| WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
| WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
| WO2024098002A1 (en) | 2022-11-04 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| WO2024104914A1 (en) | 2022-11-14 | 2024-05-23 | BioNTech SE | Rna capping efficiency assay |
| WO2024107765A2 (en) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3635956A (en) * | 1968-03-01 | 1972-01-18 | Squibb & Sons Inc | Benzothiazines related compounds derivatives and salts thereof |
| IT1059127B (it) * | 1976-04-15 | 1982-05-31 | Montedison Spa | Eteri e tioeteri benzilici o feni lici a catena alifatica lineare con terminale alogenato ad attivi ta ormonica giovanile e acaric/da |
| US5435939A (en) * | 1993-07-07 | 1995-07-25 | Isp Investments Inc. | Stable emulsifiable gel matrix and aqueous macroemulsion prepared therefrom |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| JP2002520008A (ja) | 1998-07-09 | 2002-07-09 | バイオセプト インコーポレイテッド | Ｄｎａ配列ハイブリッド形成を最適化するための改良されたペプチド核酸汎用ライブラリーの使用法 |
| WO2002092591A1 (fr) * | 2001-05-15 | 2002-11-21 | Mitsui Chemicals, Inc. | Esters acryliques et leur utilisation |
| KR100464261B1 (ko) | 2002-01-24 | 2005-01-03 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
| KR20030084444A (ko) | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
-
2004
- 2004-04-06 US US10/819,769 patent/US7211668B2/en active Active
- 2004-04-07 WO PCT/IB2004/050406 patent/WO2005009998A1/en not_active Application Discontinuation
- 2004-04-07 EP EP04726242A patent/EP1651642B1/de not_active Expired - Lifetime
- 2004-04-07 DK DK04726242T patent/DK1651642T3/da active
- 2004-04-07 KR KR1020067002202A patent/KR100752552B1/ko active IP Right Grant
- 2004-04-07 CN CN2004800220716A patent/CN1829714B/zh not_active Expired - Lifetime
- 2004-04-07 JP JP2006521712A patent/JP4441535B2/ja not_active Expired - Lifetime
- 2004-04-07 KR KR1020077006779A patent/KR20070040420A/ko not_active Application Discontinuation
- 2004-04-07 DE DE602004023951T patent/DE602004023951D1/de not_active Expired - Lifetime
- 2004-04-07 AT AT04726242T patent/ATE447569T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1651642A1 (de) | 2006-05-03 |
| WO2005009998A1 (en) | 2005-02-03 |
| DK1651642T3 (da) | 2009-12-14 |
| KR20060037415A (ko) | 2006-05-03 |
| CN1829714B (zh) | 2012-05-30 |
| KR100752552B1 (ko) | 2007-08-29 |
| EP1651642B1 (de) | 2009-11-04 |
| JP2007500184A (ja) | 2007-01-11 |
| CN1829714A (zh) | 2006-09-06 |
| KR20070040420A (ko) | 2007-04-16 |
| ATE447569T1 (de) | 2009-11-15 |
| US7211668B2 (en) | 2007-05-01 |
| JP4441535B2 (ja) | 2010-03-31 |
| EP1651642A4 (de) | 2006-11-29 |
| US20050026930A1 (en) | 2005-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004023951D1 (de) | Pna-monomer und vorstufe | |
| DE60330766D1 (de) | Pna-monomer und vorstufe | |
| ATE440089T1 (de) | Peptid-nukleinsäure-oligomere aus 1-benzol sulfonyl-3-amino säure seitenkette-4-(2-nukleo base(acetyl))piperazin-2-onen | |
| CO5640098A2 (es) | Acidos biariloximetilaren-carboxilicos | |
| NO20044807L (no) | Heratitt C virus inhibitorer | |
| NO20062339L (no) | Hepatitt C virus-inhibitoerer | |
| BR0211078A (pt) | Compostos, processo papa a preparação e uso dos mesmos, composições herbicidas, e, método para o controle de ervas daninhas em áreas cultivadas | |
| NO20062267L (no) | Hepatitt C virus inhibitorer | |
| WO2003064455A3 (en) | Macrocyclic peptides active against the hepatitis c virus | |
| WO2004014852A3 (en) | Iminothiazolidinones as inhibitors of hcv replication | |
| ATE277889T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| ATE277897T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| ATE277891T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| DK0618193T3 (da) | Nitrogenholdige, bicycliske derivater som prolyl-endopeptidaseinhibitorer | |
| BR0207831A (pt) | Compostos carbamato para uso na prevenção ou tratamento de distúrbios do movimento | |
| HUP0302193A2 (hu) | 1,4-Diazabiciklo[3.2.2]nonán-benzoxazol,-benzotiazol és -benzimidazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
| IN2012DN02546A (de) | ||
| DK1368021T3 (da) | Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af bipolær sygdom | |
| DK1408953T3 (da) | Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bipolær sygdom | |
| WO2005016916A3 (fr) | Quinolines substituées comme antimicrobiens | |
| DE60125053D1 (de) | Cephem verbindungen und diese enthaltende esbl nachweisreagenzien | |
| DE602005001704D1 (de) | Verfahren zur herstellung von alkoxycarbonylmethoxy-cyclopentanen | |
| DE602004009306D1 (de) | 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern | |
| DE50004320D1 (de) | Stabilisierte zusammensetzungen von o- und n-vinylverbindungen und verwendung von ammoniumsalzen als stabilisierungsmittel | |
| TH62866A (th) | ไดเอริลเปปไตด์เป็นสารยับยั้ง ns8- ซิรีนโปรดิเอสของไวรัสตับอักเสบ c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |